LUNGevityKristin Posted September 20, 2021 Share Posted September 20, 2021 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today presented new data from the Phase III IMpower010 study at the European Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the significant disease-free survival (DFS) benefit offered by Tecentriq ® (atezolizumab) for people with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors express PD-L1≥1%. Data from the IMpower010 trial were published simultaneously in The Lancet. In IMpower010, treatment with Tecentriq, following surgery and chemotherapy, reduced the risk of disease recurrence or death (DFS) by 34% (hazard ratio [HR]=0.66, 95% CI: 0.50–0.88) in people with Stage II-IIIA NSCLC whose tumors express PD-L1≥1%, compared with best supportive care (BSC). Safety data for Tecentriq were consistent with its known safety profile and no new safety signals were identified. The Genentech press release announcing new data from the Phase III IMpower010 study of adjuvant Tecentriq in early-stage NSCLC crossed the wire this morning at 6:05 a.m. PT, timed with the 2021 ESMO Presidential Symposium presentation and simultaneous publication in The Lancet. The full release can be viewed here: https://www.gene.com/media/press-releases/14929/2021-09-20/new-phase-iii-data-support-the-benefit-o KM_NRP 1 Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.